No abstract

Our results suggest that our diclofenac loaded lipid vesicles have significant potential as transdermal skin drug delivery system. Here, we produced cost effective lipid nanovesicles in a merely manner according to a process easily transposable to industrial scale. Graphical Abstract ᅟ.

Nombre de figures : 0 Nombre de tableaux : 4 Nombre de références : 31 Résumé Objectifs. Etudier l'impact des besoins d'information des équipes pharmaceutiques hospitalières françaises sur leurs pratiques, caractériser leur environnement documentaire et l'intérêt d'un accès à un centre d'information pharmaceutique (CIP). Matériel et méthode. Un questionnaire a été envoyé aux adhérents de l'Association pour le Développement de l'Internet en Pharmacie (ADIPh). Résultats. Deux cent soixante-dix-neuf pharmaciens hospitaliers (PhH) ont répondu. Ils jugent la recherche d'information indispensable ou souvent nécessaire et pour les deux tiers useful and would have a positive impact by facilitating and/or improving pharmaceutical decisions/interventions (89%) and in saving time (78%). Conclusion. French HP need to search for information and use tools that are mainly accessible on line. The PICs don't appear as a common source of information but HP consider that such a center would be useful.

No abstract

No abstract

Nombre de mots : 3687 Nombre de figures : 3 Nombre de tableaux : 3 Nombre de références : 24 Conflits d'intérêt : aucun *Titre/auteurs/coordonnees Nombre de mots du résumé : 370 34 35 Summary 36 analysis of the requests it receives, but improvements are possible, especially to increase its 64 area of activity.

No abstract

BackgroundPurchasing procedures in hospital are subject to the public procurement code and vary with the amounts of the purchase. The tender must be implemented when the purchase amount exceeds 200 000 Euros HT during the contract period. Although suppliers tender on estimated quantities, sometimes laboratories do not fulfil the first orders.PurposeThe objective of this study was to analyse the proportion of new markets whose orders were not honoured in the first 3 months after the beginning of the market.Material and methodsThe study focused on the local tender for generics starting in July 2015. The number of molecules for which the suppliers changed compared with the previous market were listed. The number of molecules for which the orders were not met by the contract holders in the first 3 months were also listed. Then we analysed the causes of these stock shortages. We also recorded if the upholder of the market was the best bidder or not, and if the previous market was subject to drug shortages or not.ResultsThe local market included 111 market changes. The proportion of new markets whose orders were not honoured in the first 3 months was 10%. 82% of these stock-outs concerned generics. 5 different suppliers were concerned, including 4 generic manufacturers. In 82% of cases, the successful supplier was the best bidder. 4 different causes of drug shortages were reported, the most common was a problem of quality control of raw material. In 18% of cases. the previous market was also subject to stock-outs.ConclusionDrug shortages on new markets are significant, and they may impact on quality of patient care and are time consuming for teams managing stock-outs (calls to other suppliers, orders, etc). It would be interesting to quantify the management cost of a drug shortage (human time, financial cost) and to establish indicators for the performance of suppliers that could help in the choice of future tenders.References and/or AcknowledgementsDirective 2004/18/EC of the European Parliament and of the Council of 31/03/2004 on the coordination of procedures for the award of public contracts.No conflict of interest.